Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adverum, Amryt, Argenx, Basilea, Biomarin, Croma, Cytokinetics, Daewoong, Emergent, Gilead, Janssen, Kyowa Kirin, Merck, Novartis, Novavax, Oncopeptides, Sarepta.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ainos, Antengene, Artelo, Basilea, Beigene, Defence, Degron, Kuria, Merck, Redx, Scohia.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akston, Biolexis, Calithera, GSK, Intellia, Regeneron, Sanofi.

Sanofi SA and GSK plc said new phase III data show their adjuvanted bivalent D614 and beta (B.1.351) COVID-19 vaccine candidate responded well against omicron despite it being designed to fight the original SARS-CoV-2 virus and the beta variant.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Alterity, Amryt, Astrazeneca, Biontech, CNS, Fusion, Menarini, Merck & Co., Novartis, Novavax, Radius, Realta, Rockwell, Valneva.

In a rare move, Australia’s Therapeutic Goods Administration is allowing two prescription-only COVID-19 treatments to be advertised to the public.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 3Spine.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Antisense, Apellis, Assembly, Athenex, Aura, Aveo, Chimerix, Cingulate, Coya, Cullinan Oncology, Evaxion, F-star, Immunicum, Innovation, Medc, Mendus, Medicinova, Mindset, Novartis, Pliant, Q32, Radius, Rubius, Sino, Taiho.